Samantha Prout - Amicus Therapeutics Principal Accounting Officer, Controller
| FOLD Stock | USD 9.72 0.06 0.62% |
Executive
Ms. Samantha Whiteman Prout is Principal Accounting Officer, Global Controller of the Company. Prior to joining Amicus, Ms. Prout spent nearly three years at NRG Energy, first as Controller for Home Solar division, then as the Director of Financial Reporting. Prior to joining NRG, Ms. Prout spent over 15 years at KPMG LLP, the final nine as an Audit Senior Manager serving the life science practice in NJ since 2018.
| Age | 46 |
| Tenure | 6 years |
| Address | 47 Hulfish Street, Princeton, NJ, United States, 08542 |
| Phone | 609 662 2000 |
| Web | https://amicusrx.com |
Latest Insider Transactions
Prout received a Bachelor of Arts from Gettysburg College and is a certified public accountant.Samantha Prout Latest Insider Activity
Tracking and analyzing the buying and selling activities of Samantha Prout against Amicus Therapeutics stock is an integral part of due diligence when investing in Amicus Therapeutics. Samantha Prout insider activity provides valuable insight into whether Amicus Therapeutics is net buyers or sellers over its current business cycle. Note, Amicus Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amicus Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Samantha Prout over six months ago Disposition of 7027 shares by Samantha Prout of Amicus Therapeutics at 10.66 subject to Rule 16b-3 |
Amicus Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.0116 % which means that it generated a profit of $0.0116 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6709) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.28. In addition to that, Return On Capital Employed is expected to decline to -0.13. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.39, whereas Other Assets are forecasted to decline to about 41.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| Cate McCanless | Harmony Biosciences Holdings | N/A | |
| Scott Jordan | Cytokinetics | N/A | |
| Amy Wireman | Biomarin Pharmaceutical | N/A | |
| Vimal Srivastava | Ultragenyx | 59 | |
| Jared JD | Arvinas | 55 | |
| Tim Roberts | Legend Biotech Corp | N/A | |
| Jonathan Day | Biomarin Pharmaceutical | N/A | |
| MS MBA | Kura Oncology | 50 | |
| Malini Moorthy | argenx NV ADR | 54 | |
| Francis Burrows | Kura Oncology | N/A | |
| Tricia Glover | Harmony Biosciences Holdings | N/A | |
| Audrey SPHR | Harmony Biosciences Holdings | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Katie Peng | Denali Therapeutics | N/A | |
| Stuart MD | Cytokinetics | N/A | |
| Chris JD | Denali Therapeutics | N/A | |
| Chris Walsh | Denali Therapeutics | N/A | |
| Michael Morrissey | Incyte | 60 | |
| Christian JD | Harmony Biosciences Holdings | N/A | |
| Steven JD | Cytokinetics | 65 | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | 0.0116 |
Amicus Therapeutics Leadership Team
Elected by the shareholders, the Amicus Therapeutics' board of directors comprises two types of representatives: Amicus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amicus. The board's role is to monitor Amicus Therapeutics' management team and ensure that shareholders' interests are well served. Amicus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amicus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Clark, Chief Officer | ||
| Patrik Esq, Global Officer | ||
| Patrik Florencio, Global VP | ||
| John Crowley, Executive Chairman | ||
| Simon Harford, Chief Officer | ||
| Ellen Rosenberg, General Counsel and Corporate Secretary | ||
| Ellen JD, Chief Secretary | ||
| Samantha Prout, Principal Accounting Officer, Controller | ||
| Jill Weimer, Senior Vice President of Discovery Research and Gene Therapy Science | ||
| Bradley MBA, President CEO | ||
| Andrew Faughnan, Director Relations | ||
| Diana Moore, Head Communications | ||
| Jeffrey Castelli, Vice President - Program and Portfolio Management | ||
| Jayne Gershkowitz, Chief Advocate |
Amicus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amicus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | 0.0116 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 3.1 B | ||||
| Shares Outstanding | 298.81 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 99.27 % | ||||
| Number Of Shares Shorted | 19.9 M | ||||
| Price To Earning | (9.18) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 1.629 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0116 | Return On Equity (0.67) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.